Encare: Funding, Investors & Team (Sep 2026)

Encare was established in 2009 to implement the ERAS Protocols on a global basis by - providing training to health care professionals on the ERAS Protocols - providing an interactive and web-based information system for evidence based - best practice management (EBM) The company has developed an interactive, user-friendly interface for the collection, documentation and follow-up on critical performance and quality parameters as lined out by leading clinical experts in respective protocol[1] based on, at any time, best practice and evidence. The data collected in the web-based solution is interactive and offers immediate feedback of performance, which will generate significant and sustainable improvement of efficiency and quality of care as well as generate substantial health care savings. Encare has the rights to commercialize surgical protocols developed by the ERAS Society. The company has so far rolled out the audit system to more than 120 hospitals in Canada, France, Norway, Poland, Sweden, South Africa, Switzerland, the United Kingdom, Argentina, Mexico, Colombia, Brazil, Singapore and the United States. The ERAS Society was formed in 2001 with the aim to establish evidence based protocols as best practice standards in perioperative care. ERAS Society has published a wide range of publications regarding protocols and guidelines for enhanced recovery after surgery.

Encare has raised $0k across 1 round on record. The most recent is a Series A of $0k announced in May 2023.

Encare's most recent funding round on record is a Series A of $0k, announced in May 2023.

Gustaf Nordenhok is listed as CEO at Encare.

Encare is based in Stockholm, Stockholms Lan, Sweden.

Encare is in the 11-50 employee band.

Encare's latest round of $0k is below the $4.8M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.